The Military Times reports:
U.S. Army Medical Research and Development Command has signed an arrangement with Gilead Sciences to provide the company’s investigational coronavirus drug to U.S. troops confirmed to have the COVID-19 virus. Gilead’s medication, remdesivir, was approved for clinical research in February by the FDA.
The medication, which initially was developed by the Foster City, California-based company to treat Ebola, has had some demonstrated success targeting coronaviruses, including Middle East Respiratory Syndrome, or MERS, and Severe Acute Respiratory Syndrome, SARS.
The medicine, given intravenously, is currently being tested for safety and effectiveness in two separate clinical trials in China and one by the National Institute of Allergy and Infection Diseases. In the U.S. study, the first volunteer was an evacuee from the Diamond Princess cruise ship hospitalized with the illness at the University of Nebraska Medical Center in Omaha.
Read the full article.